Population Pharmacokinetics of Anidulafungin in Critically Ill Patients

Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00378-19. doi: 10.1128/AAC.00378-19. Print 2019 Jul.

Abstract

A two-compartment pharmacokinetic (PK) population model of anidulafungin was fitted to PK data from 23 critically ill patients (age, 65 years [range, 28 to 81 years]; total body weight [TBW], 75 kg [range, 54 to 168 kg]). TBW was associated with clearance and incorporated into a final population PK model. Simulations suggested that patients with higher TBWs had less-extensive MIC coverage. Dosage escalation may be warranted in patients with high TBWs to ensure optimal drug exposures for treatment of Candida albicans and Candida glabrata infections.

Keywords: Candida; Monte Carlo simulation; anidulafungin; critical care unit; pharmacokinetics/pharmacodynamics.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anidulafungin / administration & dosage
  • Anidulafungin / pharmacokinetics*
  • Anidulafungin / therapeutic use
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / pharmacokinetics*
  • Antifungal Agents / therapeutic use
  • Body Weight
  • Candida albicans / drug effects
  • Candida glabrata / drug effects
  • Candidiasis / drug therapy*
  • Critical Illness / therapy*
  • Female
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Models, Biological

Substances

  • Antifungal Agents
  • Anidulafungin